Literature DB >> 22364796

Observational studies versus randomized controlled trials: avenues to causal inference in nephrology.

Csaba P Kovesdy1, Kamyar Kalantar-Zadeh.   

Abstract

A common frustration for practicing Nephrologists is the adage that the lack of randomized controlled trials (RCTs) does not allow us to establish causality, but merely associations. The field of nephrology, like many other disciplines, has been suffering from a lack of RCTs. The view that without RCTs, there is no reliable evidence has hampered our ability to ascertain the best course of action for our patients. However, many clinically important questions in medicine and public health, such as the association of smoking and lung cancer, are not amenable to RCTs owing to ethical or other considerations. Whereas RCTs unquestionably hold many advantages over observational studies, it should be recognized that they also have many flaws that render them fallible under certain circumstances. We provide a description of the various pros and cons of RCTs and of observational studies using examples from the nephrology literature, and argue that it is simplistic to rank them solely based on preconceived notions about the superiority of one over the other. We also discuss methods whereby observational studies can become acceptable tools for causal inferences. Such approaches are especially important in a field like nephrology where there are myriads of potential interventions based on complex pathophysiologic states, but where properly designed and conducted RCTs for all of these will probably never materialize. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22364796      PMCID: PMC3293157          DOI: 10.1053/j.ackd.2011.09.004

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  36 in total

1.  Clinical pharmacology in the Middle Ages: principles that presage the 21st century.

Authors:  D C Brater; W J Daly
Journal:  Clin Pharmacol Ther       Date:  2000-05       Impact factor: 6.875

2.  The importance of origins?

Authors:  Kamyar Kalantar-Zadeh; Mohammad Navab
Journal:  Science       Date:  2005-09-09       Impact factor: 47.728

3.  Oral active vitamin D is associated with improved survival in hemodialysis patients.

Authors:  Manuel Naves-Díaz; Daniel Alvarez-Hernández; Jutta Passlick-Deetjen; Adrian Guinsburg; Cristina Marelli; Diego Rodriguez-Puyol; Jorge B Cannata-Andía
Journal:  Kidney Int       Date:  2008-07-16       Impact factor: 10.612

4.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

5.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

6.  Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions.

Authors:  Kamyar Kalantar-Zadeh; Ryan D Kilpatrick; Charles J McAllister; Sander Greenland; Joel D Kopple
Journal:  Hypertension       Date:  2005-02-07       Impact factor: 10.190

7.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

8.  Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis.

Authors:  Elani Streja; Csaba P Kovesdy; Sander Greenland; Joel D Kopple; Charles J McAllister; Allen R Nissenson; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2008-08-29       Impact factor: 8.860

9.  Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients.

Authors:  Christian S Shinaberger; Joel D Kopple; Csaba P Kovesdy; Charles J McAllister; David van Wyck; Sander Greenland; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2008-08-13       Impact factor: 8.237

10.  Meta-analysis: vitamin D compounds in chronic kidney disease.

Authors:  Suetonia C Palmer; David O McGregor; Petra Macaskill; Jonathan C Craig; Grahame J Elder; Giovanni F M Strippoli
Journal:  Ann Intern Med       Date:  2007-12-18       Impact factor: 25.391

View more
  20 in total

Review 1.  Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis.

Authors:  Moshe Vardi; Robert W Yeh; Charles A Herzog; Wolfgang C Winkelmayer; Soko Setoguchi; David M Charytan
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-22       Impact factor: 8.237

2.  Parental health literacy and progression of chronic kidney disease in children.

Authors:  Ana C Ricardo; Lynn N Pereira; Aisha Betoko; Vivien Goh; Amatur Amarah; Bradley A Warady; Marva Moxey-Mims; Susan Furth; James P Lash
Journal:  Pediatr Nephrol       Date:  2018-06-14       Impact factor: 3.714

Review 3.  Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision-making.

Authors:  Thomas M Caparrotta; James W Dear; Helen M Colhoun; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2019-07-24       Impact factor: 4.335

4.  A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

Authors:  Sagar U Nigwekar; Sophia Zhao; Julia Wenger; Jeffrey L Hymes; Franklin W Maddux; Ravi I Thadhani; Kevin E Chan
Journal:  J Am Soc Nephrol       Date:  2016-04-14       Impact factor: 10.121

5.  Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis.

Authors:  Jessica E Miller; Miklos Z Molnar; Csaba P Kovesdy; Joshua J Zaritsky; Elani Streja; Isidro Salusky; Onyebuchi A Arah; Kamyar Kalantar-Zadeh
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-09-20       Impact factor: 2.890

Review 6.  Blood Pressure Targets in CKD: Lessons Learned from SPRINT and Previous Observational Studies.

Authors:  Elvira O Gosmanova; Csaba P Kovesdy
Journal:  Curr Cardiol Rep       Date:  2016-09       Impact factor: 2.931

7.  Examining the robustness of the obesity paradox in maintenance hemodialysis patients: a marginal structural model analysis.

Authors:  Megha Doshi; Elani Streja; Connie M Rhee; Jongha Park; Vanessa A Ravel; Melissa Soohoo; Hamid Moradi; Wei Ling Lau; Rajnish Mehrotra; Sooraj Kuttykrishnan; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; Joline L T Chen
Journal:  Nephrol Dial Transplant       Date:  2015-11-19       Impact factor: 5.992

8.  Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease.

Authors:  Csaba P Kovesdy; Jun L Lu; Miklos Z Molnar; Jennie Z Ma; Robert B Canada; Elani Streja; Kamyar Kalantar-Zadeh; Anthony J Bleyer
Journal:  JAMA Intern Med       Date:  2014-09       Impact factor: 21.873

9.  Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease.

Authors:  Miklos Z Molnar; Kamyar Kalantar-Zadeh; Evan H Lott; Jun Ling Lu; Sandra M Malakauskas; Jennie Z Ma; Darryl L Quarles; Csaba P Kovesdy
Journal:  J Am Coll Cardiol       Date:  2013-11-21       Impact factor: 24.094

10.  Survivability Prognosis for Lung Cancer Patients at Different Severity Stages by a Risk Factor-Based Bayesian Network Modeling.

Authors:  Kung-Jeng Wang; Jyun-Lin Chen; Kun-Huang Chen; Kung-Min Wang
Journal:  J Med Syst       Date:  2020-02-10       Impact factor: 4.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.